fibrotic

Release date- 28082019 - France - Inventiva (Euronext: IVA), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas of fibrosis, lysosomal storage disorders and oncology, today announced that the European Patent Office (EPO) granted on August 28, 2019 a new patent protecting the use of lanifibranor in 38 European countries in the treatment of several fibrotic diseases, including non-alcoholic steatohepatitis (NASH), until June 2035.

CM-101, is a fully humanised monoclonal antibody targeting the chemokine CCL24 that is in clinical development for the treatment of patients with liver fibrotic diseases such as NASH and Primary Sclerosing Cholangitis.

Soliton announced results of preclinical studies of the use of a new version of its acoustic pulse technology which reveal its RAP device appears to be capable of selective disruption of the fibrotic septa that contribute to the appearance of cellulite.

One of the common pathological ligands of fibrotic disease throughout the body is transforming growth factor (TGF)[beta]1 and TGF[beta]2, (5) and in the eye, the TGFP isoforms play a fundamental role in the development of corneal scarring.

Bioengineering Neural Tissue In Fibrotic Compartments of Chronic Spinal Cord Injury

The collaboration concerns a small molecule program, currently in preclinical development for the treatment of fibrotic diseases of the liver and other organs.

Previous data from the programme have identified specific genes responsible for human fibrosis to be potently suppressed by the company's BET-BD1 inhibitors thereby supporting a potential use for such inhibitors in treatment of human fibrotic diseases.

The term SRIF was first coined by Dr Anna-Luise Katzenstein et al (3) in 2010 to describe a relatively common fibrotic lesion seen exclusively in current or former smokers.

The study, which was published July 2 in Nature Medicine, found that, in people with idiopathic pulmonary fibrosis, AMP-activated protein kinase (AMPK) is lower in certain cells within the fibrotic regions of lung tissue.

The main pathological finding in NSIP is homogeneous interstitial inflammation with or without fibrosis.[1] NSIP can be categorized by cellular type or fibrotic type, according to the grade of inflammation and fibrosis.

This Small Business Innovation Research (SBIR) funding will support Phelix's continued research of Calpain therapeutics to inhibit myofibroblast generation in fibrosis for the treatment of fibrotic diseases such as IPF and NASH.